Eli Lilly plans expansion, looks to grow presence in Indian market

Eli plans to bring some of its molecules from the global pipeline to India, especially in the oncology and diabetes space

Eli Lilly will bring its pipeline of oncology and diabetes drugs to India as it looks to grow its presence in the market. The US-headquartered drug maker which has been relying on partnerships to sell its drugs in India, on Wednesday launched its patented rheumatoid arthritis drug Olumiant that they plan to market on their own.

In the last three years, it has launched eight products while in the last 22 years of its presence in the country before that it launched 10 products (molecules and molecule variants).

The US-headquartered company has a pipeline of seven molecules that are currently